中国P站

Toxicology Screening; Drug Development; Analytical Techniques; Mass Spectrometry; High-Throughput Screening; Environmental Toxicology; Forensic Toxicology; Genotoxicity Testing; Metabolomics; PBPK Modeling

Introduction

The field of toxicology plays a pivotal role in ensuring the safety of drugs and chemicals, with screening methodologies evolving rapidly to meet complex challenges. Early detection of potential adverse effects is paramount in drug development, and robust screening protocols are essential for identifying risks before they manifest in clinical settings [1].

Technological advancements have significantly expanded the capabilities of toxicological assessments, enabling more precise and comprehensive evaluations of chemical safety [2].

The development and validation of sensitive analytical techniques are crucial for accurately identifying and quantifying substances in various biological matrices, which is fundamental to both drug development and clinical toxicology [3].

Furthermore, the ability to detect and locate xenobiotics and their metabolites within tissues using techniques like mass spectrometry imaging offers new avenues for understanding toxicity mechanisms and distribution patterns [4].

In the realm of environmental health, in vitro assays provide a valuable initial step in assessing the risks posed by environmental toxicants, complementing more complex toxicological evaluations [5].

Forensic toxicology, particularly in the context of drug overdose cases, relies heavily on rapid and accurate screening methods to identify a wide range of substances, including novel and emerging drugs of abuse [6].

Metabolomics has emerged as a powerful tool, enabling the detection of subtle changes in metabolic profiles that can indicate toxic effects even before observable symptoms appear, thus aiding in early biomarker discovery [7].

The increasing prevalence of emerging contaminants, such as per- and polyfluoroalkyl substances (PFAS), necessitates the development of highly sensitive and selective analytical methods for their detection in environmental samples due to their persistence and potential toxicological implications [8].

Genotoxicity testing remains a cornerstone of drug safety assessment, employing a variety of in vitro and in vivo assays to identify potential mutagens and carcinogens, which are critical for regulatory approval processes [9].

The integration of physiologically based pharmacokinetic (PBPK) models further enhances toxicology screening by predicting the absorption, distribution, metabolism, and excretion of chemicals, thereby improving risk assessments and potentially reducing the reliance on animal testing [10].

Description

Toxicology screening is a multifaceted discipline integral to various scientific and regulatory endeavors, from pharmaceutical development to environmental monitoring. In drug development, toxicology screening identifies potential liabilities early in the process, utilizing a range of analytical techniques, including sophisticated mass spectrometry-based methods, to detect and quantify drugs and their metabolites in biological samples [1].

High-throughput screening (HTS) has revolutionized the initial stages of drug discovery by rapidly assessing large compound libraries for potential toxicities, though translating these findings to in vivo predictions remains a challenge [2].

The quantitative analysis of specific substances, such as novel psychoactive substances (NPS) in forensic and clinical settings, relies on the development and rigorous validation of highly sensitive and specific assays, often employing liquid chromatography-tandem mass spectrometry (LC-MS/MS) [3].

Mass spectrometry imaging (MSI) represents an advancement in non-targeted screening by enabling the spatial visualization of xenobiotics and their metabolites within tissue, offering insights into distribution and mechanism of toxicity [4].

For environmental safety, in vitro assays like cytotoxicity and genotoxicity tests serve as an initial screening mechanism to gauge the potential human health risks associated with environmental pollutants [5].

Forensic toxicology faces the challenge of rapidly and accurately screening for a diverse array of drugs, including those involved in overdose cases, employing techniques ranging from immunoassays to mass spectrometry [6].

The application of metabolomics offers a sensitive approach to toxicology screening by analyzing shifts in an organism's metabolic profile, which can serve as early indicators of toxic effects and aid in the discovery of relevant biomarkers [7].

The detection of emerging contaminants, exemplified by persistent organic pollutants like PFAS, requires sophisticated analytical methods capable of identifying these substances at very low concentrations in environmental matrices, given their toxicological and regulatory significance [8].

Genotoxicity testing, employing a spectrum of in vitro and in vivo assays, is a critical component of drug safety evaluation, identifying agents with mutagenic or carcinogenic potential to ensure drug approval [9].

Physiologically based pharmacokinetic (PBPK) modeling integrates biological and chemical data to predict chemical behavior within the body, enhancing toxicology screening efficiency and accuracy while potentially minimizing animal testing [10].

Conclusion

This compilation of research explores diverse aspects of toxicology screening. It highlights the critical role of analytical techniques, including mass spectrometry and LC-MS/MS, in drug development and clinical toxicology for identifying and quantifying substances in biological matrices. High-throughput screening (HTS) and metabolomics are discussed for their utility in early detection of toxicity and biomarker discovery. Environmental toxicology utilizes in vitro assays and focuses on emerging contaminants like PFAS. Forensic toxicology addresses drug overdose screening, while genotoxicity testing is emphasized for drug safety assessment. Physiologically based pharmacokinetic (PBPK) modeling is presented as a method to improve risk assessment efficiency. The importance of assay validation, interpreting results, and addressing challenges in translating findings across different models is also noted.

References

1. S S, R K, A S. (2022) .Int J Res Dev Pharmacy Life Sci 11:11(4): 185-192.

   , ,

2. M STSA, G LTA, M RARA. (2021) .Drug Discov Today 26:26(5): 1187-1193.

   , ,

3. S HK, J YP, M SL. (2023) .J Anal Toxicol 47:47(2): 158-166.

   , ,

4. Y KK, H JL, S RP. (2020) .Anal Chem 92:92(18): 12215-12224.

   , ,

5. M K, J L, P C. (2022) .Environ Sci Technol 56:56(10): 6215-6225.

   , ,

6. K K, H SL, Y GP. (2021) .Forensic Sci Res 6:6(3): 231-245.

   , ,

7. J L, S K, B P. (2023) .Chem Res Toxicol 36:36(7): 1055-1068.

   , ,

8. Y GK, H L, J P. (2022) .Anal Bioanal Chem 414:414(15): 4451-4465.

   , ,

9. S YK, M JL, K SP. (2020) .J Appl Toxicol 40:40(11): 1567-1580.

   , ,

10. J HK, S L, Y P. (2021) .Toxicol Sci 183:183(2): 221-234.

    , ,